0.61
-0.0283(-4.42%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.62 |
| Day High | 0.64 |
| Day Low | 0.6 |
| 52-Week High | 3.26 |
| 52-Week Low | 0.58 |
| Volume | 2.1M |
| Average Volume | 1.43M |
| Market Cap | 179.01M |
| PE | -0.78 |
| EPS | -0.79 |
| Moving Average 50 Days | 1.02 |
| Moving Average 200 Days | 1.69 |
| Change | -0.03 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $36.28 as of December 21, 2024 at a share price of $0.613. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 2 years ago, it would be worth $204.23 as of December 21, 2024 at a share price of $0.613.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
GlobeNewswire Inc.
Dec 10, 2024 2:00 AM GMT
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior lines of therapyManageable safety profile with no
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
GlobeNewswire Inc.
Nov 07, 2024 9:05 PM GMT
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymp
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 05, 2024 2:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies